CARING AMBASSADORS

Empowering People to be Ambassadors of their Own Health Since 1997.

LUNG CANCER PROGRAM


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer
Literature Review, July and August 2015

 

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC. Zhao X1, Wang A1, Walter V1, et al.  PLoS One. 2015 Jun 15;10(6):e0129280. doi: 10.1371/journal.pone.0129280. eCollection 2015

SIRT6 expression is associated with poor prognosis and chemosensitivity in patients with non-small cell lung cancer. Azuma Y1, Yokobori T1,2, Mogi A1, et al. J Surg Oncol. 2015 Jul 15. doi: 10.1002/jso.23975. [Epub ahead of print]

Cytology smears as diagnostic material for EGFR gene testing in non-small cell lung cancer. Powrózek T1, Krawczyk P, Pankowski J, et al. Tumori. 2015 Jun 13;0(0):0. doi: 10.5301/tj.5000360. [Epub ahead of print]

Posttranslational modifications of FOXO1 regulate epidermal growth factor receptor tyrosine kinase inhibitor resistance for non-small cell lung cancer cells. Xu ZH1, Shun WW, Hang JB, Gao BL, Hu JA. Tumour Biol. 2015 Jun 3. [Epub ahead of print]

A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in Lung cancer. Jeon YJ1, Middleton J1, Kim T2, et al. Proc Natl Acad Sci U S A. 2015 Jun 15. pii: 201504630. [Epub ahead of print]

Mercapturic Acids Derived from the Toxicants Acrolein and Crotonaldehyde in the Urine of Cigarette Smokers from Five Ethnic Groups with Differing Risks for Lung Cancer. Park SL1, Carmella SG2, Chen M2, Patel Y1, Stram DO1, Haiman CA1, Le Marchand L3, Hecht SS2. PLoS One. 2015 Jun 8;10(6):e0124841. doi: 10.1371/journal.pone.0124841. eCollection 2015.

Impact of acute exposure to WTC dust on ciliated and goblet cells in lungs of rats. Cohen MD1, Vaughan JM, Garrett B, Prophete C, Horton L, Sisco M, Ghio A, Zelikoff J, Lung-Chi C. Inhal Toxicol. 2015 Jul 21:1-8. [Epub ahead of print]

Classification of Epidermal Growth Factor Receptor Gene Mutation Status Using Serum Proteomic Profiling Predicts Tumor Response in Patients with Stage IIIB or IV Non-Small-Cell Lung Cancer. Yang L1, Tang C1, Xu B2, et al. PLoS One. 2015 Jun 5;10(6):e0128970. doi: 10.1371/journal.pone.0128970. eCollection 2015.

Keratin 34betaE12/keratin7 expression is a prognostic factor of cancer-specific and overall survival in patients with early stage non-small cell lung cancer. Pøhl M1, Olsen KE, Holst R, et al. Acta Oncol. 2015 Jun 9:1-11. [Epub ahead of print]

 

SCREENING, DIAGNOSIS AND STAGING

EGFR mutations in lung cancer: from tissue testing to liquid biopsy. Fenizia F1, De Luca A, Pasquale R1, et al. Future Oncol. 2015 Jun;11(11):1611-23. doi: 10.2217/fon.15.23.

Cost-effectiveness of Lung Cancer Screening in Canada. Goffin JR1, Flanagan WM2, Miller AB3, Fitzgerald NR4, Memon S4, Wolfson MC5, Evans WK1. JAMA Oncol. 2015 Jul 30. doi: 10.1001/jamaoncol.2015.2472. [Epub ahead of print]

FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer. Kwon W1, Howard BA, Herndon JE, Patz EF Jr. J Thorac Oncol. 2015 Jun;10(6):897-902. doi: 10.1097/JTO.0000000000000534.

Racial Differences in Outcomes within the National Lung Screening Trial. Implications for Widespread Implementation. Tanner NT1,2, Gebregziabher M1,3, Hughes Halbert C1,4,5, Payne E3, Egede LE1,6, Silvestri GA2. Am J Respir Crit Care Med. 2015 Jul 15;192(2):200-8. doi: 10.1164/rccm.201502-0259OC.

The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Rami-Porta R1, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, Rice T, Suzuki K, Thomas CF Jr, Travis WD, Wu YL; IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. J Thorac Oncol. 2015 Jul;10(7):990-1003. doi: 10.1097/JTO.0000000000000559.

CT Screening for Lung Cancer: Nonsolid Nodules in Baseline and Annual Repeat Rounds. Yankelevitz DF1, Yip R1, Smith JP1, et al. Radiology. 2015 Jun 23:142554. [Epub ahead of print]

Noninvasive CT-Based Risk Stratification of Lung Adenocarcinomas in the National Lung Screening Trial. Maldonado F1, Duan F2, Raghunath SM3, et al. Am J Respir Crit Care Med. 2015 Jun 8. [Epub ahead of print]

A computational method for clinically relevant cancer stratification and driver mutation module discovery using personal genomics profiles. Wang L, Li F, Sheng J, Wong ST. BMC Genomics. 2015 Jun 11;16 Suppl 7:S6. doi: 10.1186/1471-2164-16-S7-S6. Epub 2015 Jun 11.

Automated 3-dimensional morphologic analysis of sputum specimens for lung cancer detection: Performance characteristics support use in lung cancer screening. Wilbur DC1, Meyer MG1, Presley C1, et al. Cancer Cytopathol. 2015 Jul 6. doi: 10.1002/cncy.21565. [Epub ahead of print]

Attitudes and Perceptions About Smoking Cessation in the Context of Lung Cancer Screening. Zeliadt SB1, Heffner JL2, Sayre G1, Klein DE3, Simons C4, Williams J4, Reinke LF5, Au DH5. JAMA Intern Med. 2015 Jul 27. doi: 10.1001/jamainternmed.2015.3558. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – SURGERY

Adjuvant Chemotherapy After Lobectomy for T1-2N0 Non-Small Cell Lung Cancer: Are the Guidelines Supported? Speicher PJ1, Gu L1, Wang X1, Hartwig MG1, D’Amico TA1, Berry MF2. J Natl Compr Canc Netw. 2015 Jun;13(6):755-61.

Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults. Smith BD1, Jiang J1, Chang JY1, et al. J Geriatr Oncol. 2015 Jun 17. pii: S1879-4068(15)00048-X. doi: 10.1016/j.jgo.2015.05.002. [Epub ahead of print]

Robotic video-assisted thoracoscopic lung resection for lung tumors: a community tertiary care center experience over four years. Radkani P1, Joshi D, Barot T, Williams RF. Surg Endosc. 2015 Jun 20. [Epub ahead of print]

A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911. Yamada K1, Aono H2, Hosomi Y3,et al. Eur J Cancer. 2015 Jul 11. pii: S0959-8049(15)00646-2. doi: 10.1016/j.ejca.2015.06.120. [Epub ahead of print]

Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial. Dupuy DE1, Fernando HC2, Hillman S3, et al. Cancer. 2015 Jun 19. doi: 10.1002/cncr.29507. [Epub ahead of print]

Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancer. Takenaka T1, Inamasu E, Yoshida T, et al. Surg Today. 2015 Jun 13. [Epub ahead of print]

Comparative intention-to-treat analysis of the video-assisted thoracoscopic surgery approach to pulmonary segmentectomy for lung carcinoma‡. Witte B1, Stenz C2, Vahl CF3, Huertgen M4. Interact Cardiovasc Thorac Surg. 2015 Jun 10. pii: ivv143. [Epub ahead of print]

Postoperative complications after thoracic surgery for lung cancer. Rotman JA1, Plodkowski AJ2, Hayes SA3, et al. Clin Imaging. 2015 Jun 4. pii: S0899-7071(15)00143-6. doi: 10.1016/j.clinimag.2015.05.013. [Epub ahead of print]

Pulmonary Resection for Lung Cancer in Patients With Idiopathic Interstitial Pneumonia. Omori T1, Tajiri M2, Baba T3, et al. Ann Thorac Surg. 2015 Jun 23. pii: S0003-4975(15)00584-6. doi: 10.1016/j.athoracsur.2015.03.094. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – CHEMOTHERAPY

WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients. Liu D1, Wu C2, Jiao Y1, et al. Sci Rep. 2015 Jun 9;5:11114. doi: 10.1038/srep11114.

Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). O’Brien ME1, Gaafar R2, Hasan B3, et al. Eur J Cancer. 2015 Jun 11. pii: S0959-8049(15)00388-3. doi: 10.1016/j.ejca.2015.04.026. [Epub ahead of print]

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. Scagliotti G1, von Pawel J2, Novello S2, et al. J Clin Oncol. 2015 Jul 13. pii: JCO.2014.60.7317. [Epub ahead of print]

Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Kanda S1, Horinouchi H2, Fujiwara Y2, et al. Lung Cancer. 2015 Jul 2. pii: S0169-5002(15)00301-3. doi: 10.1016/j.lungcan.2015.06.016. [Epub ahead of print]

A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer. Liu Z1, Wei Z, Hu Y, Gao F, Hao L, Fang P, Sun S, Li J, Jiao S. Med Oncol. 2015 Aug;32(8):660. doi: 10.1007/s12032-015-0660-5. Epub 2015 Jul 14.

Use of Bevacizumab in Community Settings: Toxicity Profile and Risk of Hospitalization in Patients With Advanced Non-Small-Cell Lung Cancer. Carroll NM1, Delate T2, Menter A2, et al. J Oncol Pract. 2015 Jun 9. pii: JOP.2014.002980. [Epub ahead of print]

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: subgroup analysis of LUX-Lung 3. Kato T1, Yoshioka H2, Okamoto I3, et al. Cancer Sci. 2015 Jun 19. doi: 10.1111/cas.12723. [Epub ahead of print]

Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults. Smith BD1, Jiang J1, Chang JY1, et al. J Geriatr Oncol. 2015 Jun 17. pii: S1879-4068(15)00048-X. doi: 10.1016/j.jgo.2015.05.002. [Epub ahead of print]

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Thatcher N1, Hirsch FR2, Luft AV3, et al. Lancet Oncol. 2015 Jun 1. pii: S1470-2045(15)00021-2. doi: 10.1016/S1470-2045(15)00021-2. [Epub ahead of print]

Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer. Geater SL1, Xu CR, Zhou C, et al. J Thorac Oncol. 2015 Jun;10(6):883-9. doi: 10.1097/JTO.0000000000000517.

A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer. Ellis PM1, Leighl NB2, Hirsh V3, et al. Clin Lung Cancer. 2015 Jun 2. pii: S1525-7304(15)00142-4. doi: 10.1016/j.cllc.2015.05.010. [Epub ahead of print]

CHAMP: A Phase II Study of Panitumumab With Pemetrexed and Cisplatin Versus Pemetrexed and Cisplatin in the Treatment of Patients With Advanced-Stage Primary Nonsquamous Non-Small-Cell Lung Cancer With Particular Regard to the KRAS Status. Schuette W1, Behringer D2, Stoehlmacher J3, et al. Clin Lung Cancer. 2015 Jun 2. pii: S1525-7304(15)00141-2. doi: 10.1016/j.cllc.2015.05.009. [Epub ahead of print]

Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. Ahn JS1, Ahn YC1, Kim JH1, et al. J Clin Oncol. 2015 Jul 6. pii: JCO.2014.60.0130. [Epub ahead of print]

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Wu YL1, Zhou C2, Liam CK3, et al. Ann Oncol. 2015 Jun 23. pii: mdv270. [Epub ahead of print]

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Soria JC1, Wu YL2, Nakagawa K3, et al. Lancet Oncol. 2015 Jul 6. pii: S1470-2045(15)00121-7. doi: 10.1016/S1470-2045(15)00121-7. [Epub ahead of print]

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Soria JC1, Felip E2, Cobo M3, et al. Lancet Oncol. 2015 Jul 3. pii: S1470-2045(15)00006-6. doi: 10.1016/S1470-2045(15)00006-6. [Epub ahead of print]

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – RADIOTHERAPY

Breath-holding times in various phases of respiration and effect of respiratory training in lung cancer patients. Tibdewal A1, Munshi A1, Pathak R1, et al. J Med Imaging Radiat Oncol. 2015 Jun 3. doi: 10.1111/1754-9485.12324. [Epub ahead of print]

Comparison of Two RapidArc Delivery Strategies in Stereotactic Body Radiotherapy of Peripheral Lung Cancer with Flattening Filter Free Beams. Huang BT1, Lu JY1, Lin PX2, Chen JZ1, Kuang Y3, Chen CZ1. PLoS One. 2015 Jul 1;10(7):e0127501. doi: 10.1371/journal.pone.0127501. eCollection 2015.

Dosimetric evaluation of compensator intensity modulation-based stereotactic body radiotherapy for Stage I non-small-cell lung cancer. Tajima Y1, Nakayama H1, Itonaga T1, et al. Br J Radiol. 2015 Jun 25:20150122. [Epub ahead of print]

Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Komaki R1, Allen PK2, Wei X2, et al. Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):317-24. doi: 10.1016/j.ijrobp.2015.02.005.

Higher Versus Standard Preoperative Radiation in the Trimodality Treatment of Stage IIIa Lung Cancer. Bharadwaj SC1, Vallières E2, Wilshire CL1, et al. Ann Thorac Surg. 2015 Jun 2. pii: S0003-4975(15)00513-5. doi: 10.1016/j.athoracsur.2015.03.075. [Epub ahead of print]

Stereotactic body radiotherapy using a radiobiology-based regimen for stage I non-small-cell lung cancer: five-year mature results. Shibamoto Y1, Hashizume C, Baba F, et al. J Thorac Oncol. 2015 Jun;10(6):960-4. doi: 10.1097/JTO.0000000000000525.

A proliferation saturation index to predict radiation response and personalize radiotherapy fractionation. Prokopiou S1, Moros EG2,3, Poleszczuk J1, et al. Radiat Oncol. 2015 Jul 31;10(1):159.

 

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – NSCLC – OTHER

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES – SMALL CELL LUNG CANCER (SCLC)

Ratio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer. Zhou T1, Zhan J1, Hong S1, et al. Sci Rep. 2015 Jun 18;5:10481. doi: 10.1038/srep10481.

Genetic and Functional Analysis of Polymorphisms in the Human Dopamine Receptor and Transporter Genes in Small Cell Lung Cancer. Cherubini E1, Di Napoli A1, Noto A2,3, et al. J Cell Physiol. 2015 Jun 16. doi: 10.1002/jcp.25079. [Epub ahead of print]

Comprehensive genomic profiles of small cell lung cancer. George J1, Lim JS2, Jang SJ3, et al. Nature. 2015 Jul 13. doi: 10.1038/nature14664. [Epub ahead of print]

Frequency of O6 -methylguanine-DNA methyltransferase promoter methylation in cytological samples from small cell lung cancer. Miglio U1, Mezzapelle R1, Paganotti A2, et al. Diagn Cytopathol. 2015 Jul 7. doi: 10.1002/dc.23319. [Epub ahead of print]

Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease. Enomoto Y1, Inui N, Imokawa S, et al. Cancer Chemother Pharmacol. 2015 Jul 2. [Epub ahead of print]

Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. Foster NR1, Renfro LA, Schild SE, et al. J

Prognosis of small cell lung cancer patients with diabetes treated with metformin. Xu T1, Liang G, Yang L, Zhang F. Clin Transl Oncol. 2015 Jun 11. [Epub ahead of print]

PALLIATIVE AND SUPPORTIVE CARE

Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects. Hwang IG1, Kang JH, Oh SY, et al. Support Care Cancer. 2015 Jun 4. [Epub ahead of print]

Association of Early Patient-Physician Care Planning Discussions and End-of-Life Care Intensity in Advanced Cancer. Ahluwalia SC1, Tisnado DM2,3, Walling AM2,3, et al. J Palliat Med. 2015 Jul 17. [Epub ahead of print]

Effects of Walking on Quality of Life Among Lung Cancer Patients: A Longitudinal Study. Lin YY1, Liu MF, Tzeng JI, Lin CC. Cancer Nurs. 2015 Jul-Aug;38(4):253-9. doi: 10.1097/NCC.0000000000000176.

Nursing intervention to enhance outpatient chemotherapy symptom management: Patient-reported outcomes of a randomized controlled trial. Traeger L1, McDonnell TM2, McCarty CE1, Greer JA1, El-Jawahri A2, Temel JS2. Cancer. 2015 Jul 20. doi: 10.1002/cncr.29585. [Epub ahead of print]

Pilot Study of a Brief Behavioral Intervention for Dyspnea in Patients with Advanced Lung Cancer. Greer JA1, MacDonald JJ2, Vaughn J2, et al. J Pain Symptom Manage. 2015 Jul 9. pii: S0885-3924(15)00327-9. doi: 10.1016/j.jpainsymman.2015.06.010. [Epub ahead of print]

Effectiveness of an interdisciplinary palliative care intervention for family caregivers in lung cancer. Sun V1, Grant M1, Koczywas M2, Freeman B3, Zachariah F3, Fujinami R1, Ferraro CD1, Uman G4, Ferrell B1. Cancer. 2015 Jul 6. doi: 10.1002/cncr.29567. [Epub ahead of print]

A Structured Nursing Intervention to Address Oral Chemotherapy Adherence in Patients Boucher J1, Lucca J2, Hooper C2, Pedulla L3, Berry DL4. Oncol Nurs Forum. 2015 Jul 1;42(4):383-9. doi: 10.1188/15.ONF.383-389.

Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4. Ogawara D1, Fukuda M, Ueno S, et al. Support Care Cancer. 2015 Jun 25. [Epub ahead of print]

Increasing physical activity and exercise in lung cancer: reviewing safety, benefits, and application. Bade BC1, Thomas DD, Scott JB, Silvestri GA. J Thorac Oncol. 2015 Jun;10(6):861-71. doi: 10.1097/JTO.0000000000000536.

Elucidating patient-perceived role in “decision-making” among African Americans receiving lung cancer care through a county safety-net system. Lee SC1, Marks EG, Sanders JM, Wiebe DJ. J Cancer Surviv. 2015 Jun 16. [Epub ahead of print]

Racial Disparities in Health-Related Quality of Life After Lung Cancer Surgery: Findings From the Cancer Care Outcomes Research and Surveillance Consortium. Poghosyan H1, Stock S, Sheldon LK, Cromwell J, Cooley ME, Nerenz DR. J Thorac Oncol. 2015 Jul 20. [Epub ahead of print]

COMPLEMENTARY & ALTERNATIVE THERAPY

New geranylated flavanones from the fruits of Paulownia catalpifolia Gong Tong with their anti-proliferative activity on lung cancer cells A549. Gao TY1, Jin X2, Tang WZ3, Wang XJ4, Zhao YX2. Bioorg Med Chem Lett. 2015 Jun 17. pii: S0960-894X(15)00628-9. doi: 10.1016/j.bmcl.2015.06.035. [Epub ahead of print]

Traditional Chinese medical comprehensive therapy for cancer-related fatigue. Yang L1, Li TT, Chu YT, Chen K, Tian SD, Chen XY, Yang GW. Chin J Integr Med. 2015 Jun 24. [Epub ahead of print]

Adjuvant effects of fermented red ginseng extract on advanced non-small cell lung cancer patients treated with chemotherapy. Jiang SL1, Liu HJ, Liu ZC, et al. Chin J Integr Med. 2015 Jul 4. [Epub ahead of print]

MISCELLANEOUS WORKS

Living outliers: experiences, insights and narratives of exceptional survivors of incurable cancer. Frenkel M1,2, Gross S3, Giveon AP4, Sapire K5, Hermoni D6. Future Oncol. 2015 Jun;11(12):1741-9. doi: 10.2217/fon.15.58.

Decreasing trend in tobacco-related cancer incidence, United States 2005-2009. Underwood JM1, Richards TB, Henley SJ, Momin B, Houston K, Rolle I, Holmes C, Stewart SL. J Community Health. 2015 Jun;40(3):414-8. doi: 10.1007/s10900-014-9951-6.

Clinicopathological characteristics and prognosis of patients with adenosquamous lung carcinoma. Guo Y1, Jia L, Shao GG, Sun HW, Wang XX, Wang GJ, Ma KW. J Huazhong Univ Sci Technolog Med Sci. 2015 Jun;35(3):350-5. doi: 10.1007/s11596-015-1436-z. Epub 2015 Jun 14.

Assessing lung cancer incidence disparities between puerto ricans and other racial/ethnic groups in the United States, 1992-2010. Calo WA1, Suárez E, Soto-Salgado M, Quintana RA, Ortiz AP. J Immigr Minor Health. 2015 Jun;17(3):971-5. doi: 10.1007/s10903-014-0153-1.

A Model of Cancer Clinical Trial Decision-making Informed by African-American Cancer Patients. Wenzel JA1, Mbah O2, Xu J1, Moscou-Jackson G1, Saleem H2, Sakyi K2, Ford JG2. J Racial Ethn Health Disparities. 2015 Jun 1;2(2):192-199.

Management of Pulmonary Nodules by Community Pulmonologists: A Multicenter Observational Study. Tanner NT, Aggarwal J, Gould MK, et al. Chest. 2015 Jun 18. doi: 10.1378/chest.15-0630. [Epub ahead of print]

Evaluation of a ‘Watch and Wait’ Approach for Chemotherapy in Patients with Newly Diagnosed Advanced Non-small Cell Lung Cancer from a Diverse Community Population. Noonan K1, Tong KM1, Laskin J1, Zheng YY1, Melosky B1, Sun S1, Murray N1, Ho C2. Clin Oncol (R Coll Radiol). 2015 Jun 18. pii: S0936-6555(15)00233-2. doi: 10.1016/j.clon.2015.05.009. [Epub ahead of print]

Disparities in Lung Cancer Care and Outcomes among Elderly in a Medically Underserved State Population-A Cancer Registry-linked Database Study. Nadpara PA1, Madhavan SS2, Tworek C2. Popul Health Manag. 2015 Jun 18. [Epub ahead of print]

Calculation of lifetime lung cancer risks associated with radon exposure, based on various models and exposure scenarios. Hunter N1, Muirhead CR, Bochicchio F, Haylock RG. J Radiol Prot. 2015 Jun 17;35(3):539-555. [Epub ahead of print]

Primary Care Provider-Delivered Smoking Cessation Interventions and Smoking Cessation Among Participants in the National Lung Screening Trial. Park ER1, Gareen IF2, Japuntich S3, et al. JAMA Intern Med. 2015 Jun 15. doi: 10.1001/jamainternmed.2015.2391. [Epub ahead of print]

Preoperative Evaluation of Lung Cancer in a Community Health Care Setting. Faris N1, Yu X2, Sareen S1, et al. Ann Thorac Surg. 2015 Jun 11. pii: S0003-4975(15)00371-9. doi: 10.1016/j.athoracsur.2015.03.008. [Epub ahead of print]

Tobacco Cessation May Improve Lung Cancer Patient Survival. Amato KA1, Hyland A, Reed R, et al. J Thorac Oncol. 2015 Jun 20. [Epub ahead of print]

Disparities in Cancer Incidence, Stage, and Mortality at Boston Health Care for the Homeless Program. Baggett TP1, Chang Y2, Porneala BC3, Bharel M4, Singer DE2, Rigotti NA2. Am J Prev Med. 2015 Jul 2. pii: S0749-3797(15)00161-0. doi: 10.1016/j.amepre.2015.03.038. [Epub ahead of print]

Tobacco Cessation May Improve Lung Cancer Patient Survival. Dobson Amato KA1, Hyland A, et al. J Thorac Oncol. 2015 Jul;10(7):1014-9. doi: 10.1097/JTO.0000000000000578.

Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women’s Health Initiative Studies. Schwartz AG1, Ray RM, Cote ML, et al. J Thorac Oncol. 2015 Jul;10(7):1004-13. doi: 10.1097/JTO.0000000000000558.

Multidisciplinary Treatment for Stage IIIA Non-Small Cell Lung Cancer: Does Institution Type Matter? Samson P1, Patel A1, Crabtree TD1, et al. Ann Thorac Surg. 2015 Jul 28. pii: S0003-4975(15)00832-2. doi: 10.1016/j.athoracsur.2015.04.144. [Epub ahead of print]

Impact of care at comprehensive cancer centers on outcome: Results from a population-based study. Wolfson JA1, Sun CL1, Wyatt LP1, Hurria A1,2, Bhatia S1,3. Cancer. 2015 Jul 28. doi: 10.1002/cncr.29576. [Epub ahead of print]

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)